Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dermira Inc.

www.dermira.com

Latest From Dermira Inc.

Getting A Good Start: Sanofi Extends Dupixent's Potential To Younger Patients

Sanofi/Regeneron’s pioneering biologic, dupilumab, is growing its potential market before the advent of competing molecules. An EU approval extension, allowing use in adolescents as well as in adults, and positive Phase III results in children aged six to 11 years with severe atopic dermatitis, should help.

Dermatology Approvals

Almirall’s Dermatology Pitch Takes Shape

CEO Peter Guenter’s focus on first- and best-in-class looks like the right strategy as Spanish pharma builds critical mass in dermatology.

Sales & Earnings Strategy

Finance Watch: Gene Therapy, Targeted Oncology Driving IPOs Despite Biopharma Stock Shakiness

Public Company Edition: Jefferies report notes robust IPO market, but SVB Leerink predicts a financing slowdown. Also, Mirati raises cash for KRAS programs after Amgen's ASCO data and a strategic shift results in job cuts at ImmunoGen.

Financing Deals

First Phase III Results Keep Pfizer's Abrocitinib Among JAK Leaders In Atopic Dermatitis

Pfizer follows Lilly as the second company to report positive top-line Phase III results in AD for a JAK inhibitor. Safety is a key concern for the class, but Pfizer did not provide any details about abrocitinib's side effects.

Clinical Trials Dermatology
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Topical Delivery
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Alias(es)
  • Skintelligence Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Dermira Inc.
  • Senior Management
  • Thomas G Wiggans, CEO
    Andrew Guggenhime, CFO
    Eugene A Bauer, MD, CMO
    Chris Griffith, Chief Business & Strategy Officer
    Luis Pena, PhD, Chief Dev. Officer
    Lori Lyons-Williams, Chief Commercial Officer
  • Contact Info
  • Dermira Inc.
    Phone: (650) 421-7200
    275 Middlefield Rd.
    Ste. 150
    Menlo Park, CA 94025
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register